Align Technology said a Chinese court in Jinan ruled in its favor in a patent infringement case against Angelalign Technology’s China-based operating subsidiaries, ordering an end to the alleged use of Align’s patented orthodontic simulation and treatment-design technology. Align shares fell modestly in the latest session, closing lower as the dispute adds to the ongoing, multi-forum patent battle between the two companies.
The Jinan Intermediate People’s Court found that Angelalign infringed Align patents tied to its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system, which the court said were used to generate A7 and A7 Speed premolar extraction treatment solutions. The ruling also extended to aligner products manufactured and sold in China using the technology, and the court ordered Angelalign to stop using the technology and to cease manufacturing and selling the infringing products in China.
Key takeaways
- Price move: Align shares closed lower at $172.96, down 1.75%, with after-hours trading also slightly weaker.
- Catalyst: A Chinese court ruled in Align’s favor, finding patent infringement and ordering a stop to the technology’s use and related sales in China.
- What the court found: Use of the MasterForce simulation and ATreat treatment-design systems was found to infringe Align patents, including outputs used for A7 and A7 Speed treatment solutions.
- Financial impact: Align was awarded RMB 10 million (about $1.4 million) in damages.
- Implication: The decision intensifies enforcement pressure on Angelalign in one of the companies’ key markets, though appeal processes remain.
What the court ruling covers
According to Align Technology, the Jinan Intermediate People’s Court concluded that Angelalign’s use of Align’s MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system infringed Align’s patent rights. The court also determined that related aligner products produced and sold using the contested technology were infringing.
Align said the ruling requires Angelalign to stop using the patented technology and to halt manufacturing and selling infringing products in China. The company was additionally awarded damages of RMB 10 million, or about $1.4 million.
Broader patent dispute and potential next steps
Align noted that Angelalign may appeal the first-instance decision to China’s Supreme People’s Court. That means the immediate operational impact—while supported by a court order—could evolve depending on the appeal process and any related enforcement actions.
The court decision is part of a wider pattern of patent-enforcement steps Align has taken against Angelalign across multiple jurisdictions. Align cited a preliminary injunction issued by the Unified Patent Court in February 2026 over Angelalign’s ClinCheck Live Update technology.
Align also referenced a U.S. International Trade Commission proceeding. In July, the U.S. International Trade Commission held an evidentiary hearing involving five patents asserted by Align against Angelalign, with an initial determination expected in November 2026.
Market reaction and investor focus
In Tuesday’s trading, Align shares closed 1.75% lower at $172.96 on the Nasdaq, and the stock traded down an additional 0.30% to $172.44 in after-hours activity. While the Chinese ruling was a clear legal win for Align, the equity reaction suggests investors may be weighing the timing and uncertainty around enforcement and appeal, as well as the overall cadence of patent outcomes across different forums.
For investors, the practical question is not only whether a court found infringement, but when the remedies translate into changes in product availability, sales mix, and competitive intensity—particularly in China, where orthodontic aligner demand is a key battleground for device makers. Because Angelalign can appeal to China’s Supreme People’s Court, the durability of the remedy and the pace of any compliance will likely remain key watchpoints.
Bigger picture for the fight in digital orthodontics
Align’s case centers on digital workflow components—biomechanical simulation and treatment design systems—rather than only specific end products. That focus can broaden the scope of legal risk for competitors that rely on similar treatment-planning technology and software-driven workflows.
The multi-jurisdiction approach—from China court rulings to proceedings in Europe and the United States—signals that intellectual property strategy is increasingly central to competitive positioning in digital orthodontics. For Align, each outcome contributes to a growing record of enforcement, but the ultimate commercial impact may depend on how quickly orders are implemented and whether appeals or parallel rulings alter the initial findings.
Investors may look next for updates on Angelalign’s appeal in China, any developments tied to Align’s earlier injunction in Europe, and progress in the U.S. International Trade Commission case, where an initial determination is expected in November 2026. Closer to term, Align’s ongoing operational guidance and product execution will likely remain just as important as the litigation timeline, especially if investors continue to calibrate expectations around when legal wins can affect revenue and competitive dynamics.
